COVID-19: Meissner secures $13.4m BARDA award to produce single-use systems

Sourcebiopharma reporter
Date Published05/03/2021
Author NameJane Byrne
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Meissner Filtration Products
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2021
Capital investment ($):13.4
City reshored to:Camarillo
State(s) reshored to:CA
If relevant, work nearshored to:-
Industry(ies):Medical Equipment & Supplies
Product(s) reshoredsingle use systems for therapies
What non-domestic negative factors made offshoring less attractive?Supply chain interruption risk/Natural disaster risk/Political instability
What domestic positive factors made reshoring more attractive?Government Incentives, Impact on domestic economy
Government Incentive dollar amount:13.4 million contract
Find Reshoring Articles